Subscribe To
Abcellera biologics: bebtelovimab supply deal provides a much needed shot in the arm
AbCellera announced on Thursday Feb 10th a supply deal with the US government and Lilly for Bebtelovimab, the AbCellera developed pan COVID variant ...
February 11, 2022, 8:45 am
Preprint suggests, vir-gsk's covid-19 antibody can evade omicron sub-variant
In January, amid the omicron surge, WHO's expert panel recommended GlaxoSmithKline Plc GSK / Vir Biotechnology Inc VIR and Eli Lilly And Co's L...
February 10, 2022, 3:09 pm
Preprint suggests, vir-gsk's covid-19 antibody can evade omicron sub-variant
In January, amid the omicron surge, WHO's expert panel recommended GlaxoSmithKline Plc GSK / Vir Biotechnology Inc VIR and Eli Lilly And Co's L...
February 10, 2022, 3:09 pm
Preprint suggests, vir-gsk's covid-19 antibody can evade omicron sub-variant
In January, amid the omicron surge, WHO's expert panel recommended GlaxoSmithKline Plc GSK / Vir Biotechnology Inc VIR and Eli Lilly And Co's L...
February 10, 2022, 3:09 pm
Gsk, vir say their covid antibody treatment can neutralize fast-spreading omicron relative
Lab studies suggest the antibody treatment, one of the few shown to be effective against omicron, will ...
February 10, 2022, 6:21 am
Gsk, vir say their covid antibody treatment can neutralize fast-spreading omicron relative
Lab studies suggest the antibody treatment, one of the few shown to be effective against omicron, will ...
February 10, 2022, 6:21 am
Gsk, vir say their covid antibody treatment can neutralize fast-spreading omicron relative
Lab studies suggest the antibody treatment, one of the few shown to be effective against omicron, will ...
February 10, 2022, 6:21 am
Why did igm biosciences shares advance today?
IGM Biosciences Inc IGMS has progressed two Phase 1 trials evaluating IGM-6268, an anti-SARS-CoV-2 IgM monoclonal antibody, to treat and prevent inf...
February 9, 2022, 3:34 pm
Why did igm biosciences shares advance today?
IGM Biosciences Inc IGMS has progressed two Phase 1 trials evaluating IGM-6268, an anti-SARS-CoV-2 IgM monoclonal antibody, to treat and prevent inf...
February 9, 2022, 3:34 pm
Why did igm biosciences shares advance today?
IGM Biosciences Inc IGMS has progressed two Phase 1 trials evaluating IGM-6268, an anti-SARS-CoV-2 IgM monoclonal antibody, to treat and prevent inf...
February 9, 2022, 3:34 pm
Gsk's covid-related sales close to $2 billion, profit boost to wane in 2022
GSK racked up 1.4 billion pounds ($1.9 billion) in COVID-related sales in 2021, largely for antibody dr...
February 9, 2022, 2:27 am
Gsk's covid-related sales close to $2 billion, profit boost to wane in 2022
GSK racked up 1.4 billion pounds ($1.9 billion) in COVID-related sales in 2021, largely for antibody dr...
February 9, 2022, 2:27 am
Gsk's covid-related sales close to $2 billion, profit boost to wane in 2022
GSK racked up 1.4 billion pounds ($1.9 billion) in COVID-related sales in 2021, largely for antibody dr...
February 9, 2022, 2:27 am
Immunome shares seesaw after covid-19 antibody cocktail works against live omicron virus
Immunome Inc IMNM shares rose before falling after reporting results from testing its experimental three-anti...
February 8, 2022, 3:00 pm
Immunome shares seesaw after covid-19 antibody cocktail works against live omicron virus
Immunome Inc IMNM shares rose before falling after reporting results from testing its experimental three-anti...
February 8, 2022, 3:00 pm
Immunome shares seesaw after covid-19 antibody cocktail works against live omicron virus
Immunome Inc IMNM shares rose before falling after reporting results from testing its experimental three-anti...
February 8, 2022, 3:00 pm
Top- and bottom-line beat gives regeneron stock a boost
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) is up 1.9% to trade at $632.42 at last check, after the drug maker posted a top- and bottom-line beat for...
February 4, 2022, 10:26 am
Top- and bottom-line beat gives regeneron stock a boost
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) is up 1.9% to trade at $632.42 at last check, after the drug maker posted a top- and bottom-line beat for...
February 4, 2022, 10:26 am
Top- and bottom-line beat gives regeneron stock a boost
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) is up 1.9% to trade at $632.42 at last check, after the drug maker posted a top- and bottom-line beat for...
February 4, 2022, 10:26 am
Regeneron shares up premarket after q4 revenue doubles and blows past estimates
Regeneron Pharmaceuticals Inc. shares REGN, -0.35% rose 1.8% in premarket trade Friday, after the company doubled its fourth-quarter revenue as sales ...
February 4, 2022, 6:41 am